Search Results - "Eguia, Rachel"

A human coronavirus evolves antigenically to escape antibody immunity by Eguia, Rachel T, Crawford, Katharine H D, Stevens-Ayers, Terry, Kelnhofer-Millevolte, Laurel, Greninger, Alexander L, Englund, Janet A, Boeckh, Michael J, Bloom, Jesse D

“…There is intense interest in antibody immunity to coronaviruses. However, it is unknown if coronaviruses evolve to escape such immunity, and if so, how…”
Get full text

A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy by Greaney, Allison J, Starr, Tyler N, Eguia, Rachel T, Loes, Andrea N, Khan, Khadija, Karim, Farina, Cele, Sandile, Bowen, John E, Logue, Jennifer K, Corti, Davide, Veesler, David, Chu, Helen Y, Sigal, Alex, Bloom, Jesse D

“…Many SARS-CoV-2 variants have mutations at key sites targeted by antibodies. However, it is unknown if antibodies elicited by infection with these variants…”
Get full text

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Crawford, Katharine H D, Dingens, Adam S, Eguia, Rachel, Wolf, Caitlin R, Wilcox, Naomi, Logue, Jennifer K, Shuey, Kiel, Casto, Amanda M, Fiala, Brooke, Wrenn, Samuel, Pettie, Deleah, King, Neil P, Greninger, Alexander L, Chu, Helen Y, Bloom, Jesse D

“…Abstract Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop neutralizing antibodies that target the viral…”
Get full text

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays by Crawford, Katharine H D, Eguia, Rachel, Dingens, Adam S, Loes, Andrea N, Malone, Keara D, Wolf, Caitlin R, Chu, Helen Y, Tortorici, M Alejandra, Veesler, David, Murphy, Michael, Pettie, Deleah, King, Neil P, Balazs, Alejandro B, Bloom, Jesse D

“…SARS-CoV-2 enters cells using its Spike protein, which is also the main target of neutralizing antibodies. Therefore, assays to measure how antibodies and sera…”
Get full text

The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes by Greaney, Allison J, Eguia, Rachel T, Starr, Tyler N, Khan, Khadija, Franko, Nicholas, Logue, Jennifer K, Lord, Sandra M, Speake, Cate, Chu, Helen Y, Sigal, Alex, Bloom, Jesse D

“…Exposure histories to SARS-CoV-2 variants and vaccinations will shape the specificity of antibody responses. To understand the specificity of Delta-elicited…”
Get full text

Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein by Tortorici, M. Alejandra, Walls, Alexandra C., Joshi, Anshu, Park, Young-Jun, Eguia, Rachel T., Miranda, Marcos C., Kepl, Elizabeth, Dosey, Annie, Stevens-Ayers, Terry, Boeckh, Michael J., Telenti, Amalio, Lanzavecchia, Antonio, King, Neil P., Corti, Davide, Bloom, Jesse D., Veesler, David

“…The isolation of CCoV-HuPn-2018 from a child respiratory swab indicates that more coronaviruses are spilling over to humans than previously appreciated. We…”
Get full text

Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak by Dingens, Adam S., Crawford, Katharine H. D., Adler, Amanda, Steele, Sarah L., Lacombe, Kirsten, Eguia, Rachel, Amanat, Fatima, Walls, Alexandra C., Wolf, Caitlin R., Murphy, Michael, Pettie, Deleah, Carter, Lauren, Qin, Xuan, King, Neil P., Veesler, David, Krammer, Florian, Dickerson, Jane A., Chu, Helen Y., Englund, Janet A., Bloom, Jesse D.

“…Children are strikingly underrepresented in COVID-19 case counts. In the United States, children represent 22% of the population but only 1.7% of confirmed…”
Get full text

Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin by Lee, Juhye M, Eguia, Rachel, Zost, Seth J, Choudhary, Saket, Wilson, Patrick C, Bedford, Trevor, Stevens-Ayers, Terry, Boeckh, Michael, Hurt, Aeron C, Lakdawala, Seema S, Hensley, Scott E, Bloom, Jesse D

“…A longstanding question is how influenza virus evolves to escape human immunity, which is polyclonal and can target many distinct epitopes. Here, we map how…”
Get full text

Comprehensive mapping of adaptation of the avian influenza polymerase protein PB2 to humans by Soh, Yq Shirleen, Moncla, Louise H, Eguia, Rachel, Bedford, Trevor, Bloom, Jesse D

“…Viruses like influenza are infamous for their ability to adapt to new hosts. Retrospective studies of natural zoonoses and passaging in the lab have identified…”
Get full text

Comprehensive Profiling of Mutations to Influenza Virus PB2 That Confer Resistance to the Cap-Binding Inhibitor Pimodivir by Soh, Y. Q. Shirleen, Malone, Keara D., Eguia, Rachel T., Bloom, Jesse D.

“…Antivirals are used not only in the current treatment of influenza but are also stockpiled as a first line of defense against novel influenza strains for which…”
Get full text

Age-dependent heterogeneity in the antigenic effects of mutations to influenza hemagglutinin by Welsh, Frances C, Eguia, Rachel T, Lee, Juhye M, Haddox, Hugh K, Galloway, Jared, Van Vinh Chau, Nguyen, Loes, Andrea N, Huddleston, John, Yu, Timothy C, Quynh Le, Mai, Nhat, Nguyen T D, Thi Le Thanh, Nguyen, Greninger, Alexander L, Chu, Helen Y, Englund, Janet A, Bedford, Trevor, Matsen, 4th, Frederick A, Boni, Maciej F, Bloom, Jesse D

“…Human influenza virus evolves to escape neutralization by polyclonal antibodies. However, we have a limited understanding of how the antigenic effects of viral…”
Get more information

Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2 by Farrell, Ariana Ghez, Dadonaite, Bernadeta, Greaney, Allison J, Eguia, Rachel, Loes, Andrea N, Franko, Nicholas M, Logue, Jennifer, Carreño, Juan Manuel, Abbad, Anass, Chu, Helen Y, Matreyek, Kenneth A, Bloom, Jesse D

“…Neutralization assays are experimental surrogates for the effectiveness of infection- or vaccine-elicited polyclonal antibodies and therapeutic monoclonal…”
Get full text

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition by Greaney, Allison J., Starr, Tyler N., Gilchuk, Pavlo, Zost, Seth J., Binshtein, Elad, Loes, Andrea N., Hilton, Sarah K., Huddleston, John, Eguia, Rachel, Crawford, Katharine H.D., Dingens, Adam S., Nargi, Rachel S., Sutton, Rachel E., Suryadevara, Naveenchandra, Rothlauf, Paul W., Liu, Zhuoming, Whelan, Sean P.J., Carnahan, Robert H., Crowe, James E., Bloom, Jesse D.

“…Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being developed as therapeutics and are a major contributor to neutralizing…”
Get full text

Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection by Crawford, Katharine H D, Dingens, Adam S, Eguia, Rachel, Wolf, Caitlin R, Wilcox, Naomi, Logue, Jennifer K, Shuey, Kiel, Casto, Amanda M, Fiala, Brooke, Wrenn, Samuel, Pettie, Deleah, King, Neil P, Greninger, Alexander L, Chu, Helen Y, Bloom, Jesse D

“…Most individuals infected with SARS-CoV-2 develop neutralizing antibodies that target the viral spike protein. Here we quantify how levels of these antibodies…”
Get full text